Quick Answer
Ovid Therapeutics Inc. reported Earnings Per Share Diluted of $0.74 (loss) per share for the year ending 2023.
- Ovid Therapeutics Inc. showed an increase of +3.9% in Earnings Per Share Diluted from 2022 to 2023.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 8, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.37 (loss) per share | Q2 2020: $0.41 (loss) per share | Q3 2020: $0.28 (loss) per share | Q1 2021: $2.53 per share | Q2 2021: $0.23 (loss) per share | Q3 2021: $0.17 (loss) per share | Q1 2022: $0.23 (loss) per share | Q2 2022: $0.21 (loss) per share | Q3 2022: $0.17 (loss) per share | Q1 2023: $0.19 (loss) per share | Q2 2023: $0.18 (loss) per share | Q3 2023: $0.16 (loss) per share | Q1 2024: $0.17 (loss) per share | Q2 2024: $0.12 per share | Q3 2024: $0.20 (loss) per share.
- Over the full 4 years of available data (2020 to 2023), Ovid Therapeutics Inc.'s Earnings Per Share Diluted has grown by 46.8%.
- Historical annual values: Fiscal year 2023: $0.74 (loss) per share | Fiscal year 2022: $0.77 (loss) per share | Fiscal year 2021: $1.76 per share | Fiscal year 2020: $1.39 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: